The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant androgen pathway suppression prior to prostatectomy.
Elahe A. Mostaghel
Research Funding - GlaxoSmithKline
Peter Nelson
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
Paul H. Lange
No relevant relationships to disclose
Daniel W. Lin
No relevant relationships to disclose
Mary-Ellen Taplin
No relevant relationships to disclose
Steven P. Balk
No relevant relationships to disclose
William J Ellis
No relevant relationships to disclose
Trevor Penning
No relevant relationships to disclose
Brett Marck
No relevant relationships to disclose
Lawrence D. True
No relevant relationships to disclose
Robert Vessella
No relevant relationships to disclose
Robert B. Montgomery
Research Funding - GlaxoSmithKline